Navigation Links
CompuCyte Corporation and Program in Cellular and Molecular Medicine at Children's Hospital Boston Announce Joint Program for Quantitative Imaging Cytometry Research Services
Date:3/10/2009

BOSTON, March 10 /PRNewswire/ -- CompuCyte Corporation and the Program in Cellular and Molecular Medicine at Children's Hospital Boston (also known as the Immune Disease Institute) today announced the establishment of a joint Quantitative Imaging Cytometry program. The Program in Cellular and Molecular Medicine is an affiliate of Harvard Medical School (HMS) and is located in the Longwood Medical Area. Under the terms of the agreement, CompuCyte will make its proprietary laser scanning cytometry instrumentation and technical support programs available to trained personnel, and will provide quantitative imaging cytometry and analysis services to the larger Longwood Medical Area community.

"The joint program with CompuCyte gives our facility a new and powerful asset to offer the HMS research community. CompuCyte's instrumentation provides the ability to combine the quantitative data traditionally generated through flow cytometry with laser-scanned images of cells and tissues, without the traditional flow requirement for harsh sample-processing and the unwanted disturbance of native cells and tissue architecture normally associated with traditional cytometry," explained Dr. Natasha Barteneva, Director of the Flow and Imaging Cytometry Resource of the Program in Cellular and Molecular Medicine and manager of the joint program. "The agreement with CompuCyte expands our capacity in quantitative imaging cytometry and reinforces our commitment to providing our researchers access to the most advanced analytical technologies," stated Dr. Margaret Bradley, Chief Scientific Administrative Officer.

"Laser Scanning Cytometry (LSC) technology has become a gold standard in quantitative automated analysis of intact adherent cells, tissue specimens, tissue microarrays and small cellular samples, such as small needle aspirates," explained Dr. Elena Holden, CompuCyte's President and Chief Executive Officer. "The reputation of the Program in Cellular and Molecular Medicine for quality and scientific vigor is well known. We are enthusiastic about the opportunity to collaborate with their Flow and Imaging Cytometry Resource and to add our proprietary LSC technology to their existing infrastructure."

The Program in Cellular and Molecular Medicine at Children's Hospital Boston (also known as the Immune Disease Institute) is a non-profit research institution academically affiliated with Harvard Medical School, recognized worldwide for its discoveries that increase the body's ability to fight disease. Its mission is fundamental biomedical research to improve human health, harness inflammation, and strengthen immune defense.

CompuCyte Corporation, a private company headquartered in Westwood, Massachusetts, is a pioneer and leader in the development of quantitative imaging cytometry instrumentation based on patented laser scanning cytometry technology. The company's iCyte(R), iCys(R), and iColor(R) cytometers enable true quantitative cytometric image analysis of cellular and tissue specimens in life science research, drug safety, toxicology studies, biomarker discovery and clinical trials.


'/>"/>
SOURCE CompuCyte Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
Breaking Medicine Technology: